Interview
Archive
Associate
Graduated from: School of Medicine
Degree: PhD.
Prior to joining Booz Allen, Dr. Roos conducted his graduate studies at the Johns Hopkins School of Medicine in the Biochemistry, Cellular and Molecular Biology Program. For his thesis work, Dr. Roos investigated the role of the viral capsid protein in the human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) entry, assembly, and budding processes. He has several scientific publications and holds a provisional patent on an ultra-sensitive assay system for the detection of HIV / SIV replication.
At Booz Allen, Dr. Roos serves as a science advisor in the biological sciences for the chemical, biological, radiological, nuclear, and explosives (CBRNE) team. He leverages his technical expertise in molecular biology, biochemistry, cell biology, and virology to support several projects in the homeland defense arena for U.S. Government clients. For these clients, Dr. Roos conducts CB detection technology evaluations, reviews and develops procedures for homeland defense operations, and prepares research and development test plans. Currently, he is preparing a monograph on sampling for biological agents in the environment. Dr. Roos has contributed to standardization efforts in the CB defense community for chemical and biological sensors as well as sampling for biological threats. He has assisted in the development of a threat assessment tool for assessing CBR threats that can be delivered through the mail, as well as a methodology for evaluating the threat of biological weapons proliferation posed by research institutes in the Former Soviet Union.
President and founder of Sterilex Corporation
Graduated from: Krieger School of Arts and Sciences
Degree: Ph.D.
Dr. Shira Kramer received a BS in Biochemistry, a Master’s in Human Genetics, and a Ph.D. in Epidemiology, all from Johns Hopkins. She founded Sterilex Corporation in 1995. This company works to develop and market antimicrobial products with the goal of overcoming antimicrobial resistance. Their products are used in health care, dental care, food processing, water treatment, and industrial applications.
Before founding Sterilex, Dr. Kramer founded RidgeCom, Inc., (currently Epidemiology International) in 1984. This Philadelphia-based company focuses on epidemiological research and consulting work. They perform epidemiological studies for petroleum, chemical, pharmaceutical companies, academic institutions, and governmental agencies. Before working in industry, Dr. Kramer served on Penn’s faculty from 1978-1985. During this time, she directed an epidemiological research program in child oncology, taught graduate courses, and published numerous articles and 2 textbooks on epidemiology.
President and founder of Sterilex Corporation
Sr. Vice President,Boston Life Sciences (BLSI)
Graduated from: Krieger School of Arts and Sciences
Degree: Ph.D.
Dr. Irene Gonzalez, Ph.D. joined Boston Life Sciences (BLSI) in September of 2000 as Sr. Vice President, and Head of the laboratory facilities in Baltimore where she manages and directs the development of biotech based pharmaceutical products. Prior to joining BLSI, Dr. Gonzalez has held several senior positions including Director of Molecular Biology at BTRL-Boston Biomedica, Inc., Director of Genetic Engineering at Biotrax, Inc and grant portfolios management at the NIH-NIAID. She has been the recipient and principal investigator of numerous NIH-funded research grants and contracts, serves in the editorial boards of several scientific journals and as a NIH peer review panel member. She has been a consultant to the Department of Defense, the NIH and private corporations. Dr. Gonzalez held the positions of Assistant Professor and tenured Associate Professor at the University of Mexico. She carried out her doctoral research in Biochemistry, and post-doctoral training in Molecular Biology in the Department of Biology of Johns Hopkins University.
Sr. Vice President,Boston Life Sciences (BLSI)
Boston Life Sciences, Inc. , founded in 1992, is engaged in the research and clinical development of novel diagnostic and therapeutic products for central nervous system (CNS) disorders. The Company lead pre-clinical drug candidates target two debilitating medical conditions: Parkinson's disease and stroke. BLSI's current research collaborations include Harvard Medical School, Children's Hospital of Boston and the University of Massachusetts-Worcester.
Director of Technologies, BioCure Medical
Graduated from: Krieger School of Arts and Sciences
Degree: Ph.D.
Jonathan Heller did his Ph.D. work with Dr. Ru Chih Huang at the Department of Biology, Johns Hopkins University. He is now the director of technologies at BioCure Medical, a pharmaceutical start up company.
Director of technologies, BioCure Medical
BioCure Medical, which is based at the Centennial Campus of North Carolina State University, is developing a drug to tackle neck and shoulder cancer. It does so by using a molecule isolated from a bush called creosote that's found in the deserts of Mexico and the southwestern United States. BioCure licensed its technology from Johns Hopkins, where Ru Chih Huang, a biology professor, and John Gnabre, a postdoctoral fellow, identified the potential for compounds from the bush to be used to make drugs.
|
